Search research articles
Contact Us
Filters
Showing results (31-40 of 202) with videos related to
Page
of 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2017
Mutant p53 as a target for cancer treatment
Michael J Duffy, Naoise C Synnott, John Crown
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
May 19, 2018
Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA
Michael J Duffy, Enda W McDermott, John Crown
Translational Oncology
|
November 20, 2021
A method of separating extracellular vesicles from blood shows potential clinical translation, and reveals extracellular vesicle cargo gremlin-1 as a diagnostic biomarker
Niamh McNamee, Róisín Daly, John Crown, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
October 15, 2009
Alterations in integrin expression modulates invasion of pancreatic cancer cells
Naomi Walsh, Martin Clynes, John Crown, et al.
JAMA
|
November 3, 2005
Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer
Miguel Martin, Charles Vogel, John Crown, et al.
Clinical Chemistry
|
February 12, 2017
Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy
Michael J Duffy, Enda W McDermott, John Crown
Breast Cancer Research and Treatment
|
June 16, 2010
Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer
Anne M Friel, Claire Corcoran, John Crown, et al.
Cancer Treatment Reviews
|
February 1, 2021
MYC as a target for cancer treatment
Michael J Duffy, Shane O'Grady, Minhong Tang, et al.
Breast Cancer Research and Treatment
|
July 30, 2022
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
Minhong Tang, Shane O'Grady, John Crown, et al.
Journal of Translational Medicine
|
October 1, 2008
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Alex J Eustace, John Crown, Martin Clynes, et al.
Page
of 21
Search research articles
Search
Showing results (31-40 of 202) with videos related to
Sort By:
Page
of 21
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2017
Mutant p53 as a target for cancer treatment
Michael J Duffy, Naoise C Synnott, John Crown
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
May 19, 2018
Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA
Michael J Duffy, Enda W McDermott, John Crown
Translational Oncology
|
November 20, 2021
A method of separating extracellular vesicles from blood shows potential clinical translation, and reveals extracellular vesicle cargo gremlin-1 as a diagnostic biomarker
Niamh McNamee, Róisín Daly, John Crown, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
October 15, 2009
Alterations in integrin expression modulates invasion of pancreatic cancer cells
Naomi Walsh, Martin Clynes, John Crown, et al.
JAMA
|
November 3, 2005
Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer
Miguel Martin, Charles Vogel, John Crown, et al.
Clinical Chemistry
|
February 12, 2017
Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy
Michael J Duffy, Enda W McDermott, John Crown
Breast Cancer Research and Treatment
|
June 16, 2010
Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer
Anne M Friel, Claire Corcoran, John Crown, et al.
Cancer Treatment Reviews
|
February 1, 2021
MYC as a target for cancer treatment
Michael J Duffy, Shane O'Grady, Minhong Tang, et al.
Breast Cancer Research and Treatment
|
July 30, 2022
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
Minhong Tang, Shane O'Grady, John Crown, et al.
Journal of Translational Medicine
|
October 1, 2008
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Alex J Eustace, John Crown, Martin Clynes, et al.
Page
of 21